Search results for Mogamulizumab

Mogamulizumab, Kyinno, KB-1324

Mogamulizumab, Abbexa, abx831213

Mogamulizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CCR4/CD194, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions 8. On August 8 2018, the U. S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as Poteligeo) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy 7. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma 2.

Mogamulizumab Biosimilar - Research Grade, ichor.bio, ICH5186

Detects human CD194

Research Grade Mogamulizumab (HW634016), abinScience, HW634016

Anti-CCR4 antibody [KW-0761 (Mogamulizumab)] - Rabbit IgG (Chimeric), Abcam, AB275980

This rabbit monoclonal chimeric antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.